TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02645838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: 1. Structural motivational interviewing for one section (about 20 mins)，provided by family physician;2. Follow-up telephone call，provided by family physician.
Study: NCT02578719

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bupivacaine
Description: marcaine %0.5 20 ml flacon

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: %0.9 sodium chloride
Study: NCT03733990

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FP-1305 (bexmarilimab)
Description: The study will test for the first time in patients with cancer, an experimental medicine, called FP-1305. The study goal is to find the dose of FP-1305 that works best against cancer while it remains safe for use, tolerable and effective in patients with cancer.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FP-1305 (bexmarilimab)
Description: The study will test for the first time in patients with cancer, an experimental medicine, called FP-1305. The study goal is to find the dose of FP-1305 that works best against cancer while it remains safe for use, tolerable and effective in patients with cancer.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FP-1305 (bexmarilimab)
Description: The study will test for the first time in patients with cancer, an experimental medicine, called FP-1305. The study goal is to find the dose of FP-1305 that works best against cancer while it remains safe for use, tolerable and effective in patients with cancer.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FP-1305 (bexmarilimab)
Description: The study will test for the first time in patients with cancer, an experimental medicine, called FP-1305. The study goal is to find the dose of FP-1305 that works best against cancer while it remains safe for use, tolerable and effective in patients with cancer.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FP-1305 (bexmarilimab)
Description: The study will test for the first time in patients with cancer, an experimental medicine, called FP-1305. The study goal is to find the dose of FP-1305 that works best against cancer while it remains safe for use, tolerable and effective in patients with cancer.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FP-1305 (bexmarilimab)
Description: The study will test for the first time in patients with cancer, an experimental medicine, called FP-1305. The study goal is to find the dose of FP-1305 that works best against cancer while it remains safe for use, tolerable and effective in patients with cancer.
Study: NCT02654964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Drug Therapy
Description: Up to 3 of 73 possible interventions from the drug classes listed below will be selected based on their potency against CSCs, potential for synergy without cross-reactive toxicities, drug safety profiles, pharmacokinetics, and drug-drug interactions. Those patients that have GBM that has recurred (as defined by RANO (45)), and for whom HTS was successfully completed, will be eligible to continue to the treatment component of the study to receive the drug cocktail comprised from the following drug classes:~Antineoplastic Anti-infective Antiemetic Antihyperlipidemic Anti-inflammatory Antihistamine Antihypertensive Antidepressant Cardiotonic Alcohol antagonist Diuretic Antipsychotic NMDA receptor antagonist Antidiabetic Immunosuppressant Anticonvulsant Antimethemoglobinemic Sclerosing agent
Study: NCT03885167

Intervention type: OTHER
Intervention: Specimen Collection
Description: No interventions take place as part of study participation- only specimen collection occurs for both cohorts.

Intervention type: OTHER
Intervention: Specimen Collection
Description: No interventions take place as part of study participation- only specimen collection occurs for both cohorts.
Study: NCT02168387

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous high frequency oscillator (CHFO)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcysteine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dornase alfa
Study: NCT02265484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose+Rifaximin +Bromocriptine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose+Rifaximin +Bromocriptine
Study: NCT01029730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine: 90 mg/m2 Days 1 and 2 of 6, 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib: 1.6 mg/m2 given IV on Day 1, Day 8, and Day 15 of 6, 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab, Cycle 1: 375 mg/m2 given IV on Day 1, Day 8, and Day 15 Rituximab, Cycles 2-6: 375 mg/m2 given IV on Day 1
Study: NCT03757884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness breathing exercise
Description: Spire monitor instructed mindfulness breathing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diagnostic Checklist
Description: Checklist reminder for diagnosis

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Noise cancelling headphones
Description: Noise cancelling headphones

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Privacy tablescreen
Description: Privacy Tablescreen

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diagnostic assistance application
Description: Diagnostic assistance application
Study: NCT03339492

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RCStim Model 1114
Description: Active device emits PEMF signal; placebo/control device does not emit PEMF signal

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: RCStim Model 1114
Description: Active device emits PEMF signal; placebo/control device does not emit PEMF signal
Study: NCT01873755

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: asthma physical activity intervention
Description: School- and community-based intervention includes several components: a classroom-based physical activity program, asthma awareness week at the school, asthma education for parents and students enrolled in the study, collaboration with child's physician to ensure proper medical treatment of child's asthma asthma education for school personnel
Study: NCT02626676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Programme
Description: Educational Programme consists of lectures and group dynamics about nutrition during hemodialysis sessions.
Study: NCT02653950

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic septoplasty
Description: Endoscopic surgery; septoplasty with or without middle turbenectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional septoplasty
Description: septoplasty under direct vision
Study: NCT00352703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kepivance (Palifermin)
Study: NCT03228121

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment Then Placebo
Description: Cohort A will receive stem cells/PRP infusion during round one then placebo of normal saline infusion during round two.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placebo Then Treatment
Description: Cohort B will receive placebo of normal saline infusion during round one then stem cells/PRP infusion during round two.
Study: NCT04006184

Intervention type: OTHER
Intervention: Chart review
Description: Retrospective review of medical records at a single site with six physicians

Intervention type: OTHER
Intervention: Chart review
Description: Retrospective review of medical records at a single site with six physicians
Study: NCT02103140

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facility-based Exercise
Description: Supervised Facility-Based Exercise Intervention Arm The participants randomized to the exercise group will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months. This intervention will use heart rate and rating of perceived exertion (RPE) to define moderate intensity. Participants will exercise for the prescribed duration at a heart rate in the range of 45-65% of their maximal oxygen consumption (VO2 max), as determined during baseline testing, and with an RPE in the range of 11-14 on the 20-point scale. The exercise will primarily utilize treadmills and exercise bikes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Exercise
Description: Home-Based Exercise Intervention Group The participants randomized to this intervention arm will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months, the same as the supervised intervention group. Their exercise goal will be to achieve a total of 10,000 steps per day, as measured by pedometers. Participants will be required to have a cell phone with text messaging capabilities.
Study: NCT01344967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic Acid at a dose of 4mg will be administered by intravenous infusion over 15 minutes in at least 100mls of saline
Study: NCT01341457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2603618
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered intravenously
Study: NCT01823809

Intervention type: DEVICE
Group type: OTHER
Intervention: adenosine stress Cardiac Magnetic Resonance Imaging
Study: NCT00365989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate Enhanced Sonication
Study: NCT01676831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical resiquimod 0.06%
Description: topical resiquimod 0.06% dosing frequency begins at 3 times per week and evaluated every two weeks. Will be applied for a total of 8 weeks followed by 4 weeks rest and then followed by another 8 weeks of application with another 4 weeks rest.
Study: NCT04424329

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fibers and probiotics
Description: A blend of fibers and seven probiotics
Study: NCT01046435

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: metronidazole and amoxicillin
Description: Metronidazole 250 mg three times a day per 7 days

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: metronidazole and amoxicillin
Description: Metronidazole 250 mg three times a day per 7 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two placebos
Description: Two placebos 3 times a day for 7 days

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Two placebos
Description: Two placebos 3 times a day for 7 days
Study: NCT05099224

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Description: similar to the information included in arm/group descriptions
Study: NCT01222156

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote magnetic navigation
Description: Remote magnetic navigation of electrophysiology catheters to target intracardiac anatomical sites at mapping-ablation procedures in patients with cardiac arrhythmias

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetecs Catheter Guidance Control and Imaging system
Description: Magnetecs Catheter Guidance Control and Imaging (CGCI) system
Study: NCT00450008

Intervention type: DRUG
Group type: OTHER
Intervention: GM-CSF
Description: fixed dose of 250 mcg/m2, 3 days per week by subcutaneous injection

Intervention type: DRUG
Group type: OTHER
Intervention: thalidomide
Description: Thalidomide by oral administration at a fixed dose of 200 mg. Prophylactic Coumadin® by oral administration at a fixed dose of 2.5 mg to prevent thromboembolic events (DVT and TIA/stroke) during Thalidomide administration. Thalidomide and Coumadin will be given daily at bedtime without interruption.

Intervention type: DRUG
Group type: OTHER
Intervention: docetaxel
Description: Docetaxel will be administered by intravenous piggyback over 1 hour at 75mg/m² every 3 weeks. Pre-medication for the docetaxel infusion will consist of dexamethasone 8 mg administered orally 12 hours, 3 hours and 1 hour before docetaxel.
Study: NCT03229343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive care
Description: supportive care, systematic and joint to pneumological consultation, monthly, starting at M0 and continuing up to M6.
Study: NCT03700684

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lee Silverman Voice Treatment
Description: Persons with Parkinson's disease receive sixteen hours of voice treatment over a four week period. Participants will practice the vocal exercises at home for an additional four weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeechVive
Description: Persons with Parkinson's disease wear the SpeechVive device several hours a day over an eight week period during opportunities for communication.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Persons assigned to the non-treatment control group will not participate in voice treatment.
Study: NCT00318942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloids
Description: Isotonic or hypertonic saline or Ringer Lactate or any other crystalloids, at the necessary dose to restore hemodynamic for all ICU stay

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colloids
Description: Gelatines, Albumine, Starch, or any other colloids, at the necessary dose to restore hemodynamic (starch cumulative daily dose should not exceed 35/40 ml/kg), for all ICU stay

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloids
Description: Any crystalloids given for correction of hypovolemia during all ICU stay

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colloids
Description: Any colloids given for correction of hypovolemia during all ICU stay
Study: NCT01676831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical resiquimod 0.03%
Description: topical resiquimod 0.03% applied initially 5 times weekly for 8 weeks with adjustments up or down based upon tolerability followed by 4 weeks rest followed by another 8 weeks of treatment followed by another 4 week rest period.
Study: NCT01406418

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CR6261 5 mg/kg
Description: Administered as a single 2-hour intravenous infusion
Study: NCT00948584

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insulin dose titration system using a SMS
Description: We applied 'Insulin dose titration system in diabetic patients using a short messaging service automatically produced by a knowledge matrix' for 12 weeks in the intervention group. In the control group, a conventional insulin titration schedule was used. The insulin used in this study was Lantus (insulin glargine).
Study: NCT00594425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyl aminolevulinate (MAL) PDT
Description: Cream application followed by illumination with red light

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyl aminolevulinate (MAL) PDT
Description: Cream application followed by illumination with red light

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methyl aminolevulinate (MAL) PDT
Description: Cream application followed by illumination with red light
Study: NCT00546598

Intervention type: DEVICE
Group type: OTHER
Intervention: Total hip replacement/arthroplasty
Description: Hip replacement
Study: NCT02558829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macimorelin
Description: macimorelin acetate, 0.5 mg/kg body weight, drinking solution, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macimorelin
Description: macimorelin acetate, 0.5 mg/kg body weight, drinking solution, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin, 0.10 U/kg (0.15 U/kg if BMI \> 30 kg/m2), intravenous injection, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin, 0.10 U/kg (0.15 U/kg if BMI \> 30 kg/m2), intravenous injection, single dose
Study: NCT00745589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevelamer hydrochloride
Description: First-line higher dose (that is, 800mg TDS and up to a maximum of 1200mg TDS) sevelamer hydrochloride will be compared against low dose second-line sevelamer hydrochloride (that is, fixed dose of 400mg TDS)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevelamer hydrochloride
Description: First-line higher dose (that is, 800mg TDS and up to a maximum of 1200mg TDS) sevelamer hydrochloride will be compared against low dose second-line sevelamer hydrochloride (that is, fixed dose of 400mg TDS)
Study: NCT03573011

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]PSMA-11
Description: 18F-PET imaging

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]PSMA-11
Description: 18F-PET imaging
Study: NCT04180384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oraxol
Description: Paclitaxel:~5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13- ester with (2R,3S)-N-benzoyl-3-phenylisoserine~HM30181 methanesulfonate monohydrate:~N-(2-(2-(4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide Methanesulfonate monohydrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oraxol
Description: Paclitaxel:~5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13- ester with (2R,3S)-N-benzoyl-3-phenylisoserine~HM30181 methanesulfonate monohydrate:~N-(2-(2-(4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide Methanesulfonate monohydrate
Study: NCT01642875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Description: Standard enteral diet is administered through a nasojejunal tube. Enteral nutrition is started on the 1st postoperative day and increased daily by 20-40 ml up to the estimated level.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral nutrition
Description: Oral diet is started from the 2nd postoperative day and oral intake is advanced as tolerated
Study: NCT00538785

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Motavizumab
Description: 15 mg/kg IM administered at monthly intervals

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Palivizumab
Description: 15 mg/kg IM administered at monthly intervals
Study: NCT04661761

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Paraffin Pellets from Aurosan GmbH
Description: 1 to 2 minutes pre-chewing time chewing Paraffin Pellets from Aurosan GmbH, after which the amount of saliva is collected over a period of five minutes. The patient may chew the chewing gum once per second; after each minute the produced amount of saliva is spit in a cup, the whole amount measured after 5 minutes.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Chewing wax from the Saliva-Check Buffer from GC Europe
Description: 1 to 2 minutes pre-chewing time chewing wax from the Saliva-Check Buffer from GC Europe, after which the amount of saliva is collected over a period of five minutes. The patient may chew the chewing gum once per second; after each minute the produced amount of saliva is spit in a cup, the whole amount measured after 5 minutes.
Study: NCT04673110

Intervention type: DIAGNOSTIC_TEST
Intervention: Neutrophil to Lymphocyte Ratio and C-reactive protein
Description: Zahorec et al. identified the neutrophil-lymphocyte ratio (NLR) as an inflammation marker in critical patients, defining as the absolute neutrophil count divided by the absolute lymphocyte count

Intervention type: DIAGNOSTIC_TEST
Intervention: Neutrophil to Lymphocyte Ratio and C-reactive protein
Description: Zahorec et al. identified the neutrophil-lymphocyte ratio (NLR) as an inflammation marker in critical patients, defining as the absolute neutrophil count divided by the absolute lymphocyte count
Study: NCT05290376

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical placement of long dental implants
Description: Two interforaminal implants were placed in the canine region

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical placement of long dental implants
Description: Two interforaminal implants were placed in the canine region

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: overdenture supported by RTX attachment system
Description: Control group: Implants were loaded after three months by RTX supported overdenture study group: Implants were loaded after four weeks by RTX supported overdenture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: overdenture supported by RTX attachment system
Description: Control group: Implants were loaded after three months by RTX supported overdenture study group: Implants were loaded after four weeks by RTX supported overdenture
Study: NCT03581890

Intervention type: OTHER
Intervention: Socioeconomic position
Description: Socioeconomic position is the exposure in both study 1 and 2. Four different socioeconomic measures will be tested. The primary socioeconomic position measure is highest attained education the year before surgery (short/medium/long). Secondary measures are:~1. age- and sex-adjusted available income the year before surgery~2. Cohabitation status at the year of surgery (living alone/living with a partner) at the year of surgery.~3. Urbanicity (in four officially, predefined categories).
Study: NCT04144127

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Soccer
Description: * Soccer drills and other fitness routines (two 1-hour sessions per week)~* In person education in Life's Simple 7 to help improve life through Lifestyle changes: smoking status, physical activity, weight, diet, blood glucose, cholesterol, and blood pressure.
Study: NCT00196183

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trigger-guided catheter-ablation
Description: trigger-guided ablation of paroxysmal atrial fibrillation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trigger+substrate-guided catheter ablation
Description: trigger-+substrate guided ablation of paroxysmal atrial fibrillation
Study: NCT00631761

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational workshop
Description: The intervention group will view a 20 minute video, receive a 30 minute didactic lecture on urethrocystoscopy, and 30 minute coaching/practice performing diagnostic cystoscopy on anatomic replicas.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no intervention (usual resident activities)
Description: usual activities
Study: NCT00862420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel (SR25990)
Description: oral administration (tablets)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticlopidine
Description: oral administration (tablets)